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Abstract 
Background 
Thyroid hormone is essential for optimal human neurodevelopment and may modify the 
risk of attention-deficit hyperactivity disorder (ADHD). However, the brain structures 
involved are unknown and it is unclear if the adult brain is also susceptible to changes in 
thyroid status.  
Methods  
We used international classification of disease-10 codes, polygenic thyroid scores at 
different thresholds of association with thyroid traits (pT-values) and image-derived 
phenotypes in UK Biobank (n=18,825) to investigate the effects of a recorded diagnosis of 
thyroid disease and genetic risk for thyroid status on cerebellar and subcortical grey matter 
volume. Regional genetic pleiotropy between thyroid status and ADHD was explored using 
the GWAS-pairwise method.   
Results 
A recorded diagnosis of hypothyroidism (n=419) was associated with significant reductions 
in total cerebellar and pallidum grey matter volumes ([95%CI] = -0.14[-0.23, -0.06], p = 
0.0005 and [95%CI] = -0.12[-0.20, -0.04], p = 0.0042, respectively), mediated in part by 
increases in Body Mass Index. Whilst we found no evidence for total cerebellar volume 
alterations with increased polygenic scores for any thyroid trait, opposing influences of 
increased polygenic scores for hypo- and hyperthyroidism were found in the pallidum 
(pT<1e-3: [95%CI] = -0.02[-0.03,-0.01], p = 0.0003 and pT<1e-7: [95%CI] = 0.02[0.01,0.03], 
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p = 0.0003, respectively). Neither hypo- nor hyperthyroidism showed evidence of regional 
genetic pleiotropy with ADHD.   
Conclusions 
Thyroid status affects grey matter volume in adults, particularly at the level of the 
cerebellum and pallidum, with potential implications for the regulation of motor, cognitive 
and affective function.  
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Introduction 
Thyroid hormone (TH) is essential for optimal neurodevelopment, exemplified by the severe 
intellectual disability that affected patients with untreated congenital hypothyroidism prior 
to the introduction of neonatal screening. TH influences several aspects of 
neurodevelopment, including differentiation and proliferation of neuronal precursors, 
neuronal migration and myelination (1). Early pregnancy may be a critical window, since 
suboptimal maternal gestational thyroid function has been implicated as a risk factor for 
neurodevelopmental disorders (2,3), whilst behavioural difficulties may affect children born 
to mothers exposed to excess thyroxine in pregnancy (4). 
The brain regions involved in any potential effects of TH, however, are unclear although the 
cerebellum is emerging as a major target. Cerebellar ontogenesis is profoundly influenced 
by THs: in rodents, hypo- and hyperthyroidism affect foliation, differentiation and migration 
of granule cells, Purkinje cell arborisation and neuronal cell death (1). Such effects might 
provide a mechanistic link to the risk of neurodevelopmental disorders, since the 
cerebellum and subcortical connections are implicated as core structures in the 
pathogenesis of ADHD (5).  
However, human structural brain studies in thyroid disease are limited. In a prospective 
study of >1900 mother-child pairs from the Generation R cohort, an inverse U-shaped 
association was noted between maternal free T4 levels and offspring grey matter volume 
(6), suggesting that both low and high TH levels may adversely affect human 
neurodevelopment. Altered thyroid status may also affect grey matter volume in adults 
(7,8) although the numbers studied to date are small.  
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A new resource for relating recorded diagnoses and genetics to neuroimaging is UK Biobank. 
This prospective epidemiological study of 500,000 middle-aged volunteers (9) includes 
structural brain Magnetic Resonance Imaging (MRI) of regional grey matter volumes. We 
thus set out to investigate whether a recorded diagnosis of hypo- or hyperthyroidism in UK 
Biobank was associated with alterations in grey matter volume in adults, hypothesising that 
any effects observed would be opposing, and most apparent in the cerebellum. We 
additionally sought to explore whether genetic risk for thyroid disorders had similar effects 
on grey matter volume, and whether such a risk overlapped with that for ADHD. 
Methods 
Participants 
The UK Biobank is a population-based, volunteer cohort of 500,000 participants (40-69yrs 
old at age of recruitment) who have provided extensive medical, lifestyle and genetic data 
(9). Our study used the brain MRI imaging-derived phenotype (IDP) data of 22,000 
participants who had been scanned by UK Biobank (2014-2018) and had their data released 
by the time of study initiation. Using International Statistical Classification of Diseases and 
Related Health Problems revision-10 (ICD-10) primary and secondary diagnostic codes from 
participants’ hospital inpatient records (from 1996-present) and from self-reports of medical 
conditions (provided at UK Biobank centre), we removed individuals with severe 
neurological and psychiatric conditions (supplementary note 1 (10)). Using the thyroid-
relevant hospital in-patient ICD-10 code recordings (E00-E07), we derived a categorical 
variable of having had any-time recorded diagnoses for hypothyroidism, hyperthyroidism or 
other thyroid disorders (supplementary note 1 (10)). For genetic analyses, we further 
removed those subjects with ICD-10 or self-reported thyroid disorder. Additional imaging 
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6 
and genetic exclusion criteria and quality control are outlined below. Ethical approval for UK 
Biobank was granted by the North West Multi-Centre Ethics Committee. Data for this study 
were obtained under application number #17044. 
MRI data 
A full description of the imaging acquisition, quality control and imaging-derived phenotype 
(IDP) generation from UK Biobank can be found elsewhere (11). Briefly, UK Biobank 
participants attended one of two imaging sites using the same scanner design (3-Tesla 
Siemens Skyra scanner; 32 channel head coil) and underwent an extensive imaging protocol, 
which included a T1-weighted structural scan (3D Magnetization Prepared Rapid Acquisition 
Gradient Echo with 1mm3 isotropic resolution) whose data we used here. We used the 
released IDP produced by UK Biobank using processing tools from FMRIB (Functional 
Magnetic Resonance Imaging of the Brain) Software Library (12) (FSL), including FAST (13) 
(FMRIB’s Automated Segmentation Tool) registration of cerebellar lobules atlas and FIRST 
(14) (FMRIB’s Integrated Registration and Segmentation Tool) registration of subcortical 
regions atlas. Of the cerebellar lobule IDPs, we excluded Crus I vermis due to its small size 
and likely low signal-to-noise ratio. We grouped these regions of interest by hemisphere, 
and all cerebellar lobules into a single total cerebellar volume measure, analysing any 
lobule-specific effects as secondary analyses. We chose this approach because no 
cerebellar-specific registration process was applied, likely reducing the signal-to-noise ratio 
in the cerebellum, because cerebellar lobules are highly correlated and because the lobule 
boundaries show only small association with functional boundaries, meaning that detection 
of strong lobule-specific effects was deemed less likely. Subjects with any covariate imaging 
value (see below) deemed as outliers (>5 × median absolute deviation from the overall 
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median) were removed from further analysis and, of these, those with remaining  outlier 
values were excluded from each respective region analysis (supplementary table 1 (10)). 
Genetic data 
A full description of UK Biobank’s data collection, quality control and imputation process can 
be found elsewhere (http://www.ukbiobank.ac.uk/scientists-3/genetic-data/). Locally, we 
further applied additional quality control of the imaging-sample raw genotypes using the 
genotypeqc function (https://github.com/ricanney/stata). All Stata functions described 
leverage PLINK (15) (v1.90b5.4; www.cog-genomics.org/plink/1.9/). Briefly, all markers were 
harmonised to genome build hg19 and common nomenclature was applied based on the 
Haplotype Reference Consortium (HRC) r1.1. We excluded markers based on individual 
missingness (>2%), low minor allele count (<5),  deviations from Hardy-Weinberg 
equilibrium (p<10–10) and from expected Minor Allele Frequency (MAF; defined as 4 
standard deviations (SD) from the reported 1000 genomes project phase-3 GBR MAF). 
Participants were excluded based on their overall marker missingness (>2%) and marker 
heterozygosity (>4 × SD from sample mean). Using bim2ancestry_keep function 
(https://github.com/ricanney/stata) we limited to GBR ancestry  (>4 × SD from 1000 
genomes project phase-3 GBR sample mean for the first 3 principal components (PCs)) and 
using bim2unrelated we removed one of each pair of close relatives (>0.0442 kinship 
coefficient i.e. 3rd degree relatives). A total of 7,726,488 markers were included in 
downstream analysis.   
Polygenic score training data were obtained from the most recent Genome Wide 
Association Study (GWAS) meta-analysis on circulating thyroid hormone levels, which tested 
up to 72,168 participants of European ancestry and provided summary statistics for thyroid 
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8 
stimulating hormone (TSH) and free thyroxine (fT4) levels in subjects with TSH levels within 
the cohort reference range, as well as for elevated (hypothyroidism) and reduced 
(hyperthyroidism) TSH compared to these ranges (16). Each thyroid-disorder GWAS was 
based on 7,858,695 and 7,980,324 genetic markers respectively. We utilised the summary 
statistics across genders, rather than sex-specific summary statistics. Summary statistics 
were harmonised to hg19 build and HRC reference nomenclature using summaryqc 
(https://github.com/ricanney/stata).  
Polygenic scores were created using the PLINK summaryqc2score wrapper function 
(https://github.com/ricanney/stata). Regions of known high linkage disequilibrium (LD) (17) 
were excluded prior to calculating polygenic scores. Scores were subsequently calculated 
from LD-independent (r2<0.2) markers for hyper- and hypothyroidism, and TSH and free-T4 
level summary statistics for Single Nucleotide Polymorphism (SNP) inclusion p-value 
thresholds (pT) of pT<0.5, <0.1, <0.05, <0.01, <1e-3, <1e-4, <1e-5, <1e-6, <1e-7 and <1e-8. An 
individual’s polygenic score is a linear weighted sum of their genotype values weighted by 
their effect sizes for each thyroid trait.  
 
Statistical methods 
For our analyses we used univariate multiple linear regression in R(3.6.0) (https://www.R-
project.org/). Our first primary analyses investigated the effect of hypothyroid and 
hyperthyroid diagnoses on total cerebellar and subcortical volumes. The control group in 
this analysis were those with no thyroid-related diagnoses. For each model we controlled 
for potential confounding by other imaging variables of head size (volumetric scaling applied 
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for registration, analogous to the inverse of head size; 25000), imaging centre attended (54-
2.0), X-, Y- and residual Z-head position in the scanner (25756, 25757, 25758, with Z-position 
having starting table-Z position regressed out; 25759), along with demographic covariates of 
age (21003-2.0, quadratic), sex (31) and their interaction. Histograms were used to confirm 
normally distributed residuals. We tested for any mediation of BMI on overt diagnoses 
differences using the mediation package (18) with 1000 bootstrapping simulations, while 
also controlling for the above covariates. Using the medsens function (18) we tested for 
violations of the sequential ignorability assumption that there are no unmeasured 
confounders of the mediator-outcome pathway. In the subset with no overt or self-reported 
thyroid disorders, we repeated the above analysis using polygenic scores for thyroid-related 
traits. For these genetic predictors, in addition to the above covariates, we also controlled 
for BMI (log transformed; 21001-2.0) as well as the first 10 genetic PCs to correct for 
residual population structure. Secondary analyses investigated any lobule-specific effects. 
Standardised  coefficients reflecting changes in units of SD, corresponding 95% confidence 
intervals (CI) and the variance explained in the outcome uniquely attributable to the 
phenotype of interest (ΔR2; calculated by subtracting each model R2 with the phenotype 
against those without) are provided. The Benjamini-Hochberg method (19) was used to 
control the False Discovery Rate (FDR<0.05) for the number of models assessed in each 
section (thyroid diagnoses and polygenic scores).  
We also aimed to investigate evidence for regional pleiotropy between ADHD and hypo- and 
hyperthyroidism using the GWAS-pairwise method (20) utilising recent ADHD GWAS meta-
analysis summary statistics of 20,183 ADHD cases and 35,191 controls (21). Following 
application of the same quality control protocols outlined above, 5,907,045 genetic markers 
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10 
were carried forward for analyses. We performed two-sample meta-analysis using METAL 
(22), with the second pair in the GWAS performed with the reported  and with the sign of 
the  flipped so as to not avoid omitting those markers with opposing effects. Three models 
were examined; model-1 where the association is driven by Thyroid trait GWAS (gwas-1), 
model-2 where it is driven by ADHD GWAS (gwas-2), and model-3 where it is driven by 
signal at both gwas-1 and gwas-2. For any marker, model-3 was accepted if pmodel-3<5e-8 and 
independently pgwas-1 and pgwas-2 were both observed at p<1e-5.  
Results 
Effects of thyroid disorders on cerebellar and subcortical brain volumes 
After exclusion, 18,825 individuals (Age (meanSD) = 62.77.45, Male =48%) remained 
(table 1), of whom 538 (3.1%) had an ICD-10 thyroid-related disorder (n=419 (2.2%) 
hypothyroidism, n=33 (0.2%) hyperthyroidism, and n=86 (0.5%) other thyroid disorder or a 
history of both hypo- and hyperthyroidism) (table 1). Hypothyroidism cases were, on 
average, 2 years younger than controls (p = 5.09e-7), while hyperthyroidism cases showed 
no significant difference (p = 0.17) and both disorders were more common in females. 
Correcting for demographic and imaging covariates, head size (inverse of head size; see 
methods) was not significantly altered in either hypo- or hyperthyroidism cases compared 
to controls ([95%CI] = 0.023[-0.052,0.098], p=0.55 & [95%CI] = -0.023[-0.493,0.034], 
p=0.09, respectively). 
For our main analyses, we tested for differences in total cerebellar and subcortical volumes 
in cases of hypo- and hyperthyroidism compared to controls (table 2; figure 1). For 
hypothyroidism, we found significant (FDR<0.05) reductions in bilateral total cerebellar and 
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11 
pallidum volumes ([95%CI] = -0.14[-0.23,-0.06], p=0.001 and [95%CI] = -0.12[-0.20,-0.04], 
p=0.004, respectively). There were no volume changes in hyperthyroidism cases (p>0.05). 
Exploring the effects across the cerebellum (supplementary table 2(10); supplementary 
figure 1(10)), we found significant reductions across most cerebellar lobules in 
hypothyroidism cases, aside from superior posterior vermal regions (VI-VIIIa vermis). Only 
one region, the Crus II hemispheric volume, indicated possible opposing effects between 
hypo- and hyperthyroidism ([95%CI] = -0.11[-0.20,-0.03], p = 0.02 & [95%CI] = 
0.40[0.09,0.71], p = 0.01, respectively).  
Since BMI was higher in subjects with hypothyroidism (table 1) we tested whether it 
mediated any of the significant relationships observed between hypothyroidism and brain 
morphometry. We confirmed this for total cerebellar (40%[25,82%] mediated, p < 2e-16) 
and pallidum volume (23%[12,61%] mediated, p < 2e-16) though significant average direct 
effects (ADE) remained (supplementary table 3 (10)). The results, however, were sensitive to 
violations of sequential ignorability, and if relatively small residual correlation between BMI 
and brain volumes exist, then these would make this assumption invalid (rho > -0.2 & -0.1 
for cerebellar and pallidal analyses). 
 
Effects of genetic risk for thyroid disorders on cerebellar and subcortical brain volumes 
For our genetic analyses, we removed ICD-10 or self-reported cases of any thyroid-related 
diagnoses, leaving N=18,255 subjects (supplementary table 4 (10)). We tested for the effect 
of increasing thyroid polygenic score for hypo- and hyperthyroidism, and TSH and fT4 levels 
on cerebellar and subcortical volumes, controlling the FDR for the number of volumes, 
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thyroid traits and SNP p-value thresholds (pT-values) assessed. The number of GWAS-
significant SNPs at each pT-value is provided in supplementary table 5 (10). We found no 
relationships across any thyroid trait at any pT-value reaching our significance threshold 
when controlling FDR<0.05 (figure 2, supplementary table 6 (10)), though opposing effects 
in the pallidum of increasing polygenic scores for hyper- and hypothyroidism were close to 
this threshold (pT<1e-7: [95%CI] = 0.02[0.01,0.03], p = 0.0003 and pT<1e-3: [95%CI]  = -
0.02[-0.03,-0.01], p = 0.0003, respectively). This included finding no evidence for total 
cerebellar volume alterations with increased polygenic score for any thyroid trait (p>0.05). 
While this was also reflected at the cerebellar lobule level for most thyroid traits, there was 
a fairly consistent pattern of lobule volume increases at more stringent hyperthyroidism 
polygenic score pT-values, though none reached our significance threshold following 
multiple comparison correction (supplementary table 7 (10); supplementary figure 2 (10)).  
 
Genetic association between thyroid disorders and ADHD 
Finally, we investigated evidence for regional genetic pleiotropy between common genetic 
variants important for our thyroid disorders and those for ADHD disorder. Using GWAS-
pairwise analyses, we found that neither hypothyroidism nor hyperthyroidism showed any 
evidence for regional genetic pleiotropy with ADHD; with no SNPs observing model-3 pmodel-3 
< 5e-8, while also observing both pgwas-1 and pgwas-2 < 1e-5.  
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Discussion 
This is the first study to have examined an effect of thyroid status on regional brain volumes 
in adults on a large scale. We used a combination of a recorded diagnosis and genetic risk 
scores to confirm an effect of thyroid status on grey matter volume, notably at the level of 
the cerebellum and pallidum.  
A recorded diagnosis of hypothyroidism was associated with modest reductions in 
cerebellar and pallidum volume when controlling for overall head size. These findings are 
consistent with clinical observations of cerebellar dysfunction in hypothyroidism and 
Hashimoto’s encephalopathy (23), as well as rodent studies demonstrating high TH receptor 
expression in the cerebellum during development (24) and TH effects on cerebellar cell 
differentiation, arborisation, migration and death (1). In addition to its well-established roles 
in motor coordination, the cerebellum also regulates various cognitive and affective 
processes (25). These are mediated via widespread connections to cortical and subcortical 
regions, including direct connections with the pallidum (26) and other structures within the 
basal ganglia. The volume reductions in hypothyroidism were evident across cerebellar 
lobules, with the Crus II region, a non-motor cerebellar region with high basal ganglia 
connectivity (26),  being the only lobule showing both hypothyroidism-related reductions 
and hyperthyroidism-related increases in volume. The findings of our study thus indicate 
that disruption to cerebellar-pallidal pathways might be a key neuronal feature of thyroid 
disorders.  
We found no change in hypothyroidism cases in other subcortical regions or in head size 
derived from the scaling applied to T1 images. These findings differ to those of a recent 
study, in which 70 adults with elevated TSH had significantly lower total brain volume than 
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euthyroid controls, while low TSH was not associated with change in brain volume (27). In 
both cases, total grey matter volume was unaffected by TSH status. A reduction in 
hippocampal volume in subjects with elevated TSH was also apparent in this and another 
study (28). Since we did not observe any alterations in hippocampal or total volume, these 
differences may suggest that hippocampal effects occur only in active disease and resolve 
with appropriate treatment. Alternatively, the differences may relate to our larger sample 
size, different populations or the diagnoses used. We did not find any significant alterations 
in subjects with a diagnosis of hyperthyroidism, although the volume effects were broadly 
opposite to hypothyroidism and we were likely underpowered in view of the much smaller 
subject numbers. 
Since hypothyroidism is associated with weight gain, we undertook mediation analysis to 
examine the influence of BMI, finding that the effects of hypothyroidism on grey matter 
volume reduction were mediated in part by BMI. To our knowledge, this finding has not 
been reported previously, although increased BMI is recognised as a risk factor for grey 
matter volume loss in in older age (29).  Our findings may thus have important implications 
for physicians managing patients with hypothyroidism, placing an emphasis on minimisation 
of weight gain to protect against grey matter volume loss. However, since our analysis was 
retrospective, further studies assessing causality should be performed. For instance, in 
addition to BMI, an effect of elevated weight on reducing MRI signal-to-noise ratio, 
including via increased head motion (30,31), cannot entirely be excluded and should be 
explored in future studies, in addition to the effect of smoking status, which is known to 
influence thyroid function (32) as well as affecting brain volume (33). Since direct effects on 
volume loss still remained when controlling for BMI, other mechanisms may also be in 
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operation, including reduced T3 signalling, as patients established on levothyroxine 
replacement for hypothyroidism display reduced serum T3 levels despite normalisation of 
TSH (34).  
We undertook our genetic sub-study with an aim of replicating findings from recorded 
diagnosis. We found little evidence for an effect of polygenic scores on grey matter volume 
in most regions of interest, with the exception of the pallidum in which opposing influences 
of polygenic scores for hypo- and hyperthyroidism were found, albeit of borderline 
significance. However, it should be recognised that only a relatively small proportion of the 
variance in thyroid function is explained by the latest GWAS, with reduced power especially 
for increased or decreased TSH since subjects with known thyroid disease were excluded. 
Nevertheless, the effects on grey matter volume in the pallidum raise the possibility of a 
shared influence of genetic risk for hypo- and hyperthyroidism with grey matter volume in 
this subcortical region. Large-scale genetic-imaging analysis has led to the discovery of 
several genetic variants important for subcortical development (35) and our results indicate 
that exploration of genomic loci showing pleiotropy for both pallidal development and 
thyroid disorder might prove fruitful. 
Finally, in light of several studies suggesting a link between thyroid status and ADHD risk, 
and common morphometric alterations at the level of the cerebellum (5), we sought to 
establish if there was any genetic evidence for pleiotropy between thyroid disorders and 
ADHD using GWAS-pairwise analyses. Since we found no evidence for pleiotropy, this may 
imply that any excess risk of ADHD related to disturbed thyroid status relates to 
environmental influences, such as altered maternal thyroid function, rather than shared 
genetic aetiology. Our recent observations of an increased risk of behavioural disturbances 
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in children born to mothers exposed to excess thyroxine replacement in pregnancy (4) 
supports the view that the in utero environment is a critical window. This risk may be 
mediated, at least in part, through excess TH receptor alpha signalling in view of the high 
prevalence of ADHD reported in children with resistance to thyroid hormone beta (36). 
Our study has a number of strengths, including the large sample size and integrated genetic 
and imaging analysis. This provides a template by which future studies could be undertaken, 
for example when the imaging dataset in UK Biobank extends to its intended target of over 
100,000 participants. However, our study also has several limitations, including a lack of 
thyroid function tests, which necessitated our use of recorded diagnosis and polygenic 
scores as markers of thyroid status. The prevalence of hypothyroidism was also lower than 
the most recent UK data. We suspect that this may relate to differences in 
sociodemographic and health-related characteristics of participants in UK Biobank, who are 
more likely to be older, live in less socioeconomically deprived areas and with fewer self-
reported health conditions (37). We also confined our analyses to grey matter volume; since 
TH also affects myelination, future studies might also include an assessment of white matter 
volume, especially in childhood and adolescence when the expansion in myelin deposition is 
profound. Fourthly, as with almost all genetic imaging analyses, we found that the variance 
explained in our volumes by genetic risk scores was relatively low. Methods to improve this 
in future studies, including larger samples, more complex genetic analyses (e.g. gene*gene 
and gene*environment interactions) and use of cerebellar-specific registration tools, would 
be invaluable. Finally, anatomical lobules are unlikely to offer the best separation of 
cerebellar function, with atlases defined by resting and task-based functional MRI scans 
available (25,38). 
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To conclude, our study provides evidence for an effect of thyroid status on grey matter 
volume in adults, most notably at the level of the cerebellum and pallidum. These 
observations extend our understanding of the influence of TH on neuronal structure in the 
human brain. However, further studies are needed to replicate and extend our findings, 
including a focus on imaging datasets in childhood and adolescence, where any effects of 
altered thyroid exposure on neurodevelopment might be expected to be more profound.    
 
Data availability 
Some or all data generated or analyzed during this study are included in this published 
article or in the data repositories listed in References. 
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Figure Legends 
Figure 1: Effect on total cerebellar (CB) and subcortical volumes of a diagnosis of 
hypothyroidism and hyperthyroidism compared to normative controls. All values are 
following correction for demographic and imaging covariates. Standardised beta coefficients 
(β) and 95% confidence intervals (CI) are provided. * signifies results with FDR<0.05. 
 
Figure 2: Effect on total cerebellar (CB) and subcortical volumes of increasing polygenic 
score (PGS) for hypothyroidism, hyperthyroidism, free thyroxine (fT4) and thyroid 
stimulating hormone (TSH) across the different SNP p-value inclusion thresholds (pT). All 
values are following correction for demographic, genetic and imaging covariates. 
Standardised beta coefficients (β) and 95% confidence intervals (CI) are provided. Of note, 
no results were below our FDR<0.05 threshold. 
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Tables 
Table 1: Demographic information for the study cohort, including those with ICD-10 
diagnosis of hypothyroidism, hyperthyroidism, other thyroid-related disorders and those 
without any thyroid-related diagnosis (normative controls).  
 Hypothyroidis
m 
(n=419) 
Hyperthyroidis
m 
(n=33) 
Other  
(n=86) 
No 
(n=18287) 
Total 
Sex 
     
F 338 (80.7%) 29 (87.9%) 75 (87.2%) 9440 (51.6%) 9882 (52.5%) 
M 81 (19.3%) 4 (12.1%) 11 (12.8%) 8847 (48.4%) 8943 (47.5%) 
Age (years) 
     
Mean (SD) 64.5 (7.32) 60.8 (9.05) 63.1 (6.53) 62.6 (7.45) 62.7 (7.45) 
Median [Min, 
Max] 
65.0 [47.0, 
78.0] 
62.0 [46.0, 78.0] 
64.0 [46.0, 
74.0] 
63.0 [45.0, 
80.0] 
63.0 [45.0, 
80.0] 
Body Mass 
Index      
Mean (SD) 28.0 (4.92) 28.6 (5.55) 26.3 (4.23) 26.6 (4.39) 26.6 (4.41) 
Median [Min, 
Max] 
27.3 [17.9, 
49.2] 
27.8 [17.9, 46.5] 
25.7 [17.1, 
40.2] 
25.9 [13.4, 
58.0] 
26.0 [13.4, 
58.0] 
Missing 11 (2.6%) 2 (6.1%) 5 (5.8%) 428 (2.3%) 446 (2.4%) 
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Table 2: Effect on total cerebellar (CB) and subcortical volumes of diagnosis of 
hypothyroidism and hyperthyroidism compared to normative controls  
  ICD-10 Hypothyroidism ICD-10 Hyperthyroidism 
 ΔR2 β CI.l CI.u p FDR β CI.l CI.u p FDR 
CB Total 4.95E-04 -0.144 -0.225 -0.063 0.001 0.008  0.157 -0.128 0.442 0.281 0.636  
Thalamus 1.10E-04 -0.069 -0.134 -0.003 0.039 0.156 0.063 -0.167 0.293 0.591 0.795  
Caudate 1.08E-04 -0.068 -0.147 0.011 0.094 0.300  0.066 -0.213 0.345 0.642 0.795  
Putamen 1.55E-04 -0.085 -0.158 -0.011 0.024 0.129 0.002 -0.256 0.260 0.986 0.986 
Pallidum 3.30E-04 -0.121 -0.204 -0.038 0.004 0.034  -0.093 -0.383 0.197 0.529 0.795  
Accumbens 5.42E-05 -0.024 -0.108 0.060 0.579 0.795  -0.155 -0.450 0.140 0.302 0.636  
Hippocampus 3.99E-05 -0.043 -0.127 0.041 0.318 0.636 -0.004 -0.300 0.292 0.979 0.986 
Amygdala 9.49E-06 0.002 -0.087 0.091 0.966 0.986  0.073 -0.240 0.386 0.646 0.795  
 
All values are following correction for demographic and imaging covariates in the model. 
Variance of volumes uniquely explained by thyroid ICD-10 hospital record variable (ΔR2), 
Standardised B-coefficients (β), 95% confidence intervals (lower and upper CI), uncorrected 
p-values and controlled False Discovery Rate (FDR) q-values for the number of genetic 
predictors are provided. Bold signifies results FDR<0.05. 
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Figure 1 
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Figure 2 
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